Cellectis SA
(OTCPK:CMVLF)
$
3.47
(0%)
Market Cap: 275.30 Mil
Enterprise Value: 183.39 Mil
PE Ratio: 0
PB Ratio: 4.79
GF Score: 59/100 Cellectis SA at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022 / 05:00PM GMT
Release Date Price:
$3.21
Matthew (Trades, Portfolio)atorre
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone, and thank you for joining us for Day 4 of the Goldman Sachs Healthcare Conference. We're really pleased to have Cellectis here. And with us, we have Bing Wang, CFO. So just to get started. So Cellectis is a clinical-stage biotech company using its platform to develop cell therapies.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot